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Abstract
Background: The risk of developing Barrett’s esophagus (BE) and/or esophageal adenocarcinoma (EAC) is
associated with specific demographic and behavioral factors, including gender, obesity/elevated body mass index
(BMI), and tobacco use. Alterations in DNA methylation, an epigenetic modification that can affect gene expression
and that can be influenced by environmental factors, is frequently present in both BE and EAC and is believed to
play a role in the formation of BE and its progression to EAC. It is currently unknown whether obesity or tobacco
smoking influences the risk of developing BE/EAC via the induction of alterations in DNA methylation. To
investigate this possibility, we assessed the genome-wide methylation status of 81 esophageal tissues, including BE,
dysplastic BE, and EAC epithelia using HumanMethylation450 BeadChips (Illumina).
Results: We found numerous differentially methylated loci in the esophagus tissues when comparing males to
females, obese to lean individuals, and smokers to nonsmokers. Differences in DNA methylation between these
groups were seen in a variety of functional genomic regions and both within and outside of CpG islands. Several
cancer-related pathways were found to have differentially methylated genes between these comparison groups.
Conclusions: Our findings suggest obesity and tobacco smoking may influence DNA methylation in the esophagus
and raise the possibility that these risk factors affect the development of BE, dysplastic BE, and EAC through
influencing the epigenetic status of specific loci that have a biologically plausible role in cancer formation.
Keywords: Barrett’s esophagus, Esophageal adenocarcinoma, DNA methylation, Obesity, Waist-to-hip ratio, Tobacco use
Background
The incidence of esophageal adenocarcinoma (EAC) has
been increasing in the USA for several decades for reasons
that are not entirely clear but may be related to the in-
creasing prevalence of risk factors such as obesity [1]. The
precursor lesion for EAC is Barrett’s esophagus (BE), a
metaplastic condition where the squamous-lined esopha-
geal mucosa is replaced by specialized intestinal mucosa.
A minority of individuals with BE will develop EAC
through a progression sequence in which BE transitions to
BE with low-grade dysplasia (LGD), BE with high-grade
dysplasia (HGD), and ultimately to EAC [2].
It is recognized that both genetic and epigenetic alter-
ations arise in the esophagus during the development
and progression of BE and EAC [3–5]. Epigenetic alter-
ations, primarily in the form of hypermethylated or
hypomethylated CpG dinucleotides in the DNA, have
been described in BE and EAC using both candidate
gene approaches and microarray-based strategies. Hyper-
methylation of CpGs in CpG islands in promoter regions
has been associated with the repression of transcrip-
tion of some genes, and hypermethylation of CpGs in
gene bodies is associated with increased gene expression
[6, 7]. The effects of DNA methylation on the regulation
of gene expression have supported the plausibility
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that alterations in DNA methylation can affect disease
processes in people.
Aberrant DNA methylation has been shown to occur
early in the BE → dysplastic BE → EAC progression se-
quence [8]. The aberrant methylation of numerous
cancer-related genes, such as CDKN2A, as well as global
alterations in DNA methylation has been observed in BE,
and many of these epigenetic alterations are also found in
dysplastic BE and EAC [8–13]. However, despite the near
universal observation of altered DNA methylation in BE
and EAC, the mechanisms driving aberrant DNA methy-
lation in the esophagus, as in most other pre-neoplastic
and neoplastic tissues, remain elusive.
The risk of developing BE and/or EAC is associated
with specific demographic and behavioral factors, in-
cluding obesity/elevated body mass index (BMI) and
tobacco use [14, 15]. Numerous mechanisms through
which these factors may affect BE and/or EAC forma-
tion have been proposed [16, 17]; however, no assess-
ment of effects on the epigenome in the esophagus
has been made to date. There is evidence that certain
environmental, behavioral, and demographic factors
can influence the epigenetic state, which suggests that
the behavioral factors associated with BE and EAC
may act by inducing alterations in the methylation sta-
tus of DNA [18]. For example, alterations in the
methylation status of CpG islands in the promoter re-
gions of genes implicated in obesity, appetite control,
and metabolism have been shown to occur in DNA
isolated from blood and breast tissue of obese com-
pared to lean individuals [19–22]. Tobacco smoking,
meanwhile, has been associated with alterations in
DNA methylation of multiple cancer-related genes in
studies focused on single candidate genes as well as in
genome-wide methylation studies of prostate cancer,
the bronchial epithelium, and peripheral blood mono-
nuclear cells [23–26].
These observations led us to use HumanMethyla-
tion450 (HM450) BeadChips to evaluate epigenome-
wide patterns of DNA methylation in a collection of
human esophageal tissue samples, including cases of
Barrett’s esophagus (BE), Barrett’s with low- or high-
grade dysplasia, and esophageal adenocarcinoma (EAC).
We were interested in determining whether BMI, to-
bacco smoking, and/or gender were associated with in-
creased or decreased DNA methylation at specific CpG
dinucleotides or in particular genomic regions, which
would support a possible functional role in the patho-
genesis of EAC. We also focused on whether epigenetic
alterations linked with these demographic features asso-
ciated with particular molecular or cancer-related path-
ways in order to assess for possible mechanisms through
which alterations in the DNA methylation status may be
involved in the formation of BE and/or EAC.
Results
Differences in the methylation status of genes in obesity-
related pathways are associated with BMI status
Obesity has been consistently associated with an in-
creased risk for developing both BE and EAC, yet little
is known about the mechanisms involved in this elevated
risk [27, 28]. While it is likely that both somatic genetic
and epigenetic alterations play a role in the pathogenesis
of BE and EAC, there is currently very little information
about the relationship between Barrett’s esophagus and
esophageal adenocarcinoma, obesity, and aberrant DNA
methylation. From the 81 samples we analyzed on the
HM450 array, body mass index (BMI) data were av-
ailable for 46 cases, including 15 BE, 14 LGD, nine
HGD, and eight EAC cases. We classified each of these
samples as arising in the setting of either high BMI
(BMI > 30) or low BMI (BMI ≤ 30). For female patients
(N = 7), there were three in the low BMI and four in the
high BMI groups. First, we determined whether the BE
samples from the high BMI group (N = 11) had global
DNA methylation alterations that were more closely
related to HGD and/or EAC cases compared to the BE
samples from study subjects with low BMI (N = 4). We
found that high and low BMI BE cases tend to cluster
together and that the high BMI BE cases did not appear
to be more related to HGD/EAC than the low BMI BE
cases (data not shown).
Next, we assessed for differentially methylated loci
(DML) that varied between the combined esophageal
tissue samples (BE, LGD, HGD, EAC) from individ-
uals with high vs. low BMI. Using criteria for DML of
a p value <0.001 and Δβ between high BMI and low
BMI > 0.10, we found a total of 974 DML between
the high and low BMI groups, including 226, 471,
and 277 DML located in promoter, intragenic, and
intergenic regions, respectively. A dendrogram depicting
the DML between high and low BMI patients is shown in
Fig. 1. One hundred and eighty-two (182) DML were
located in CpG islands and 376 were located in CpG
island shores (within 2 kb of a transcription start site
[29]). We also found 352 DML (36.1 % of the total 974
DML) that were cancer associated, which we defined as
loci that were differentially methylated between the
normal squamous (SQ; N = 12) and EAC (N = 24) cases
on the HM450 array. In general, the high BMI cases
showed increased methylation at the DML, with 872 out
of 974 DML (89.5 %) demonstrating elevated methylation
in high vs. low BMI cases. The DML with the greatest
statistical significance (p < 5 × 10−6) associated with BMI
are shown in Table 1.
We also evaluated the association of BMI with tissue
DNA methylation in the separate histologic types of
esophageal tissues (e.g., BE, BE with LGD, BE with
HGD, and EAC). We compared methylation in the high
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BMI (N = 4) vs. low BMI (N = 11) BE cases, the high
BMI (N = 7) vs. low BMI (N = 7) LGD cases, and the
high BMI (N = 9) vs. low BMI (N = 8) HGD/EAC cases.
Table 2 summarizes the DML found when comparing
these groups. The methylation status of the high com-
pared to low BMI BE cases with respect to genomic
regions and CpG island location is shown in Fig. 2. In
general, in the BE cases, DML located in promoters and
CpG islands were hypermethylated in high BMI vs. low
BMI cases, whereas DML located elsewhere were hypo-
methylated in high BMI vs. low BMI cases. In contrast
to this, DML in the HGD/EAC cases were hypermethy-
lated at all functional regions as well as CpG island
shores, shelves [30], and open seas in the high BMI vs.
low BMI cases but not at CpG islands (Fig. 2).
We also looked to see if any of the DML between
the high and low BMI BE cases overlapped with any
of the DML when comparing BE to EAC, in order to
determine if methylation alterations in obese individ-
uals with BE might be associated with progression to
HGD/EAC. We did find nine probes that overlapped
between these groups, including those targeting the
genes HLA-DPA1, TBR1, OSR2, TMEM63A, CD300E,
and UBD/FAT10. UBD/FAT10, which we found to be
hypomethylated in high BMI BE patients, is of inter-
est as this gene has been shown to be overexpressed
in hepatocellular carcinoma (HCC) and is thought to
modulate the β-catenin/TCF4 pathway and drive HCC
invasion and metastasis [31].
Because of the potential for DNA methylation alterations
to modify gene expression, we next assessed the methyla-
tion status of CpGs located in genes associated with signal-
ing pathways and biological mediators implicated in
obesity-associated cancers [17, 32, 33] in the esophageal tis-
sues from the subjects with low vs. high BMI. With regard
to the insulin and insulin growth factor 1 (IGF-1) related
pathways, we observed increased methylation of IGFBP1
(average beta = 0.11 in low BMI cases and 0.27 in high BMI
cases) and IRS2 (average beta = 0.11 in low BMI cases and
0.36 in high BMI cases) in the high BMI compared to low
BMI BE cases. Both genes were hypermethylated in the
high BMI cases in a CpG island located within exon 1. Un-
like with BE cases, genes of the insulin or IGF-1 pathways
did not show altered methylation in high vs. low BMI cases
in the LGD, HGD, or EAC tissue sets. We also examined
molecular pathways associated with adipose inflammation,
which has been shown to mediate obesity-related cancer
[32] and found the proinflammatory gene IL-1β (IL1B) to
be hypermethylated in high vs. low BMI cases when we
assessed the combined esophageal tissue sets. We
also found hypermethylation of IL1B in the HGD/
EAC cases from high BMI subjects. For the combined
cases, the average beta was 0.25 (SD = 0.10, 95 % CI = 0.21–
0.30) in low BMI cases and 0.35 (SD = 0.12, 95 % CI =
0.30–0.41) in high BMI cases and for the HGD/EAC
cases, average beta was 0.20 (SD = 0.08, 95 % CI =
0.12–0.27) in low BMI cases and 0.38 (SD = 0.11,
95 % CI = 0.30–0.47) in high BMI cases. Of interest,
Fig. 1 Dendrograms depicting DML when comparing high to low BMI cases. Because absolute differences in methylation (i.e., beta values)
between cases were small, these heatmaps illustrate relative differences in methylation between cases instead of absolute beta values. a High vs.
low BMI, all cases (BE, LGD, HGD, and EAC) combined. b High vs. low BMI, BE cases. c High vs. low BMI, HGD/EAC cases
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adiponectin and leptin have also been implicated in
obesity-associated cancer [34, 35]; however, we did
not observe any differences in the DNA methylation
status of genes involved in leptin or adiponectin path-
ways in any of the esophageal tissue sets in the high
vs. low BMI subjects.
There are numerous differentially methylated regions
(DMR) between individuals with high and low BMI in
esophageal tissues
The analysis described above was focused on the
methylation status of individual CpG dinucleotides
located in promoters, gene bodies, and intergenic
Table 1 Differentially methylated loci (p < 5 × 10−6): high vs. low BMI cases (BE, LGD, HGD/EAC combined)














cg11839020 LRRC8D 0.29 0.41 (↑) 4.06E-09 5′UTR Shore 1.59–1.78* 1.44–1.86* N
cg11027822 ITGA6 0.62 0.72 (↑) 1.97E-07 Body Open sea 1.57–3.96* 1.48–2.66* Y
cg25872281 TMUB1 0.66 0.81 (↑) 3.56E-07 TSS1500;
body
Island 1.32* NS N
cg22984132 TMUB1 0.51 0.62 (↑) 3.64E-07 TSS1500;
body
Island 1.32* NS N
cg26314478 ESPNP 0.49 0.60 (↑) 3.86E-07 Body Shelf NS NS N
cg09458237 HSPA12B 0.51 0.66 (↑) 4.46E-07 TSS1500 Shore 1.37* 1.89–6.50* Y
cg06393286 FAM43B 0.48 0.36 (↓) 4.64E-07 1st exon Island NS NS Y
cg09058554 SLC25A33 0.39 0.51 (↑) 6.40E-07 Body Shore NS 1.23* Y
cg14950321 PLIN5 0.31 0.42 (↑) 7.21E-07 Body Shore 4.17* NS N
cg02134660 FAM83B 0.52 0.72 (↑) 1.17E-06 TSS1500 Shore NS NS N
cg25302888 TMUB1 0.65 0.77 (↑) 1.23E-06 TSS1500;
body
Island 1.32* NS N
cg05137975 C6orf168 0.53 0.70 (↑) 1.52E-06 Body Open sea NS 3.64* N
cg16957569 IDO2 0.56 0.69 (↑) 1.68E-06 TSS1500 Open sea NS NS N
cg00831127 EPHB2 0.26 0.49 (↑) 2.33E-06 Body Shore 1.62–6.30* 1.40–7.83* Y
cg25229964 CNKSR1 0.59 0.71 (↑) 2.39E-06 TSS1500 Open sea NS NS N
cg19513232 CAMK2A 0.39 0.52 (↑) 2.43E-06 Body Open sea NS NS N
cg10976975 BMP10 0.72 0.83 (↑) 2.53E-06 5′UTR; 1st
exon
Open sea NS NS N
cg04025965 TMUB1 0.58 0.72 (↑) 2.66E-06 TSS1500;
body
Island 1.32* NS N
cg02233614 PFKFB2 0.29 0.39 (↑) 2.82E-06 5′UTR Shore 1.32* 1.12* N
cg06020352 IRF8 0.36 0.50 (↑) 2.92E-06 TSS1500 Shore 1.80–6.36* 3.85–7.56* N
cg08526705 MYC 0.61 0.74 (↑) 2.99E-06 Body Shore NS 3.89* N
cg08943714 HECA 0.28 0.42 (↑) 3.66E-06 Body Open sea NS NS N
cg17161520 TBC1D10C 0.46 0.57 (↑) 3.92E-06 Body Shelf NS 1.14* N
cg10583322 MEGF11 0.49 0.65 (↑) 4.15E-06 Body Open sea NS 1.69* Y
cg02059867 RAPGEFL1 0.42 0.57 (↑) 4.50E-06 1st exon;
5′UTR
Island NS NS N
5′UTR = 5′ untranslated region; TSS1500 = 1500 bp’s upstream from transcription start site; Shore = DNA sequence up to 2 kb from CpG island; Shelf = DNA
sequence 2–4 kb from CpG island; Open sea = DNA sequence >4 kb from CpG island; NS = not significant; ^ = relative gene expression data obtained from
www.oncomine.org; *p ≤ 0.05; (↑)/(↓) = increase/decrease in methylation in high BMI group vs. the low BMI group















BE 288 85 (29 %) 129 (45 %) 74 (26 %) 113 (39 %) 108 (37 %) 60 (21 %)
LGD 372 120 (32 %) 166 (45 %) 86 (23 %) 226 (61 %) 166 (45 %) 252 (68 %)
HGD/EAC 270 73 (27 %) 156 (58 %) 41 (15 %) 53 (20 %) 111 (41 %) 40 (15 %)
DML defined by p value <0.001 and Δβ value (high BMI vs. low BMI) > 0.10 while controlling for age
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regions. In light of recent studies suggesting gene
expression changes are highly correlated with the
aberrant methylation of large regions of DNA, called
differentially methylated regions (genomic areas where
numerous contiguous CpGs demonstrate significant
concordant methylation alterations) [36, 37], we next
assessed for differentially methylated regions (DMR)
in the esophageal tissue samples from the low vs.
high BMI subjects. Among the BE cases, there were
DMR in 10 genes that differed between the high and
low BMI groups (FWER < 0.10, Δβ > 0.10, and at least
two contiguous CpG dinucleotides differentially meth-
ylated). Examples of two of these genes, TFAP2C and
DIP2C, are shown in Fig. 3. Among the HGD/EAC
cases, 31 DMR were identified using the same cri-
teria, including regions in the genes ZNF790 and
SIM2 (Fig. 3). We did not find any DMR within
prominent genes in the insulin, IGF-1, TNF-α, or
leptin pathways.
A comparison of genes showing differential methylation
between high vs. low BMI cases demonstrates the
involvement of cancer-related pathways and gene sets
We used the NCI Pathway Interaction Database (NCI-
PID), Kyoto Encyclopedia of Genes and Genomes (KEGG)
database, and the list of Gene Ontology (GO) terms to
identify biological processes or pathways that were
over- or under-represented based on genes containing
Fig. 2 Genomic location, relationship to CpG islands, and methylation status of DML when comparing high vs. low BMI esophageal samples. In
each panel, “Hypo” refers to percentage of DML that are hypomethylated in high BMI vs. low BMI samples; “Hyper” refers to percentage of DML
that are hypermethylated in high BMI vs. low BMI samples. On the Y axis, DMLs (%) refers to the percentage of the total DML that are associated
with a particular genomic location (a, d) or CGI relationship (b, e). Percentages may add up to more than 100 % because some probes were classified
with more than one designation. Beta values are equivalent to percent methylation. a DML when comparing high BMI to low BMI BE cases by
genomic region. Non-promoter regions were enriched with hypomethylated loci (p = 0.008), whereas promoter regions were borderline-enriched
with hypermethylated loci (p = 0.06). b Location of DML when comparing high BMI to low BMI BE cases with respect to CpG island location. Non-CGI
regions were enriched with hypomethylated loci (p = 8.4 × 10−8), whereas CpG island regions were enriched with hypermethylated loci (p = 0016).
c Box and whisker plots showing distribution of DML that are hypomethylated in the high vs. low BMI BE cases (left) and hypermethylated in the high
vs. low BMI BE cases (right). d DML when comparing high BMI to low BMI HGD/EAC cases by genomic region. Promoter regions were enriched with
hypomethylated loci (p = 2.7 × 10−6). e Location of DML when comparing high BMI to low BMI HGD/EAC cases with respect to CpG island location.
CpG island regions were enriched with hypomethylated loci (1.9 × 10−6), whereas non-island regions were enriched with hypermethylated loci
(p = 6.5 × 10−5). f Box and whisker plots showing distribution of DML that are hypomethylated in the high vs. low BMI HGD/EAC cases (left) and
hypermethylated in the high vs. low BMI HGD/EAC cases (right)
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DML between the esophageal tissue sets in the subjects
with either high or low BMI status. As mentioned pre-
viously, we defined “cancer-associated” probes as those
that were differentially methylated between EAC and
SQ cases on the array.
Among the BE cases, we found one NCI-PID path-
way, “direct p53 effectors”, which includes the differen-
tially methylated gene RDX from our dataset, associated
with methylation differences between high and low BMI
groups. There were 13 KEGG pathways (including “cell
adhesion molecules”) and 77 GO terms (including “re-
sponse to growth hormone” and “biological adhesion”)
that were represented in the differentially methylated
genes in the BE samples from the high vs. low BMI
subjects. The list of GO terms is shown in Additional
file 1: Table S2.
With respect to the HGD/EAC cases, there were no
NCI-PID pathways that were significantly associated
with methylation differences between high and low BMI
status after restricting our analysis to only cancer-related
genes. There was one KEGG pathway (“Wnt signaling”)
and 87 GO terms (such as “tissue morphogenesis” and
“response to TGF-beta”) differentially methylated be-
tween HGD/EAC cases from subjects with high BMI vs.
low BMI (p value <0.05) (Additional file 2: Table S3).
Gender-related differences in DNA methylation in
esophageal tissues
Little is known about gender-specific variations in DNA
methylation in most tissues, including the esophagus.
Previous studies have shown that repetitive elements
and specific CpG dinucleotides isolated from blood
samples demonstrate modestly increased methylation
in males compared to females [38, 39]. Another study
of four candidate genes in colorectal adenocarcinoma
cells demonstrated that males had increased methyla-
tion of MTHFR, CALCA, and MGMT compared to
females [40].
Fig. 3 Selected genes containing differentially methylated regions (DMR) when comparing tissue samples from subjects with high vs. low BMI.
The presence of concordant aberrant methylation is seen in the contiguous CpG sites in these DMR. Each panel contains the gene name and
chromosomal location, alternate transcripts, exons and introns (large and small orange boxes), location of CpG islands (green boxes), DML (blue
and pink dots), and the DMR (yellow box). Cases with BMI ≥30 are shown in pink and BMI < 30 in blue. a TFAP2C gene, BE cases. b DIP2C gene, BE
cases. c ZNF790, HGD/EAC cases. d SIM2 gene, HGD/EAC cases
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To the best of our knowledge, a genome-wide analysis
of gender differences in DNA methylation in the esopha-
gus has not been previously reported. Using HM450
array analysis of BE, HGD, and EAC esophageal samples
from 118 males and 23 females, we found numerous
CpG sites that were differentially methylated between
the genders after excluding probes on the X and Y chro-
mosomes and after accounting for differences in the age
between the men and women in our study. When we
combined the BE, HGD, and EAC cases, there were
1092 DML, including 369, 421, and 402 DML located in
promoter, intragenic, and intergenic regions, respect-
ively. From this list, there were 402 DML where the
mean beta value difference between males and females
was >0.10 and p value was <0.001. These DML were as-
sociated with CpGs in genes such as DUSP22, a regula-
tor of estrogen receptor alpha mediated signaling,
FRG1B, which is involved in pre-mRNA splicing, and
CGREF1, which mediates cell-cell adhesion in a calcium-
dependent manner. Of these 402 DML, 327 (81.3 %)
were more highly methylated in females. The DML with
the greatest statistical significance (p < 5 × 10−6) between
males and females are listed in Table 3. Of interest, half
of the top DML were located in CpG islands.
Tobacco use is associated with DNA hypermethylation in
the esophagus
Tobacco smoking, which is a well-known risk factor for
Barrett’s esophagus and EAC, has been associated with
alterations in DNA methylation in peripheral blood lym-
phocytes [26, 41]. However, little is known about the re-
lationship between smoking and DNA methylation
alterations in esophageal tissues, including BE and EAC.
To investigate this further, we assessed the relationship
between smoking and aberrant DNA methylation in
samples from subjects for which we had data on tobacco
use. We divided cases into “smokers” (which included
both current and former smokers) and “nonsmokers;”
we did not further segregate smokers by current smok-
ing status, pack-years, etc. due to the relatively small
number of cases available. We first compared BE non-
smokers (N = 7) to BE smokers (N = 9) using principal
component analysis (PCA) to determine whether methy-
lation patterns of BE smokers more closely resembled
the patterns we observed in LGD, HGD, and/or EAC
cases compared to BE nonsmokers. When we examined
the 1000 loci with the most variable methylation be-
tween groups, we did not find the BE smokers were
grouped more closely with LGD/HGD/EAC than BE
nonsmokers (data not shown).
Next, we evaluated 54 esophageal samples of various
histologic types (BE, LGD, HGD, and EAC) for global al-
terations in DNA methylation associated with tobacco
smoking. After controlling for differences associated
with the histological diagnosis (BE, LGD, or HGD/EAC),
we found a total of 256 DML between the smokers (N = 40)
and nonsmokers (N = 14) (Δβ > 0.10, p < 0.001). Heatmaps
depicting the DML between smokers and nonsmokers are
shown in Fig. 4.
These DML included 98, 40, and 118 loci located in
promoter, intragenic, and intergenic regions, respect-
ively. Two hundred forty-two (242) of the 256 DML
(94.5 %) were more highly methylated in smokers com-
pared to nonsmokers, and 105 of the 256 DML (41.0 %)
affected cancer-associated genes, as based on the criteria
described above. The DML with the greatest statistical
significance (p < 1 × 10−4) associated with smoking are
shown in Table 4.
We also evaluated the association of tobacco use with
DNA methylation in the separate esophageal tissue types
(i.e., BE, LGD, HGD, and EAC). We assessed for DML
in the BE smokers (N = 9) vs. BE nonsmokers (N = 7)
and in the HGD/EAC smokers (N = 19) vs. HGD/EAC
nonsmokers (N = 7) while controlling for age differences.
We were not able to compare the LGD cases as all sam-
ples were from smokers. Table 5 summarizes the DML
we identified for these comparisons and shows the func-
tional genomic locations of the loci when comparing
these groups. The methylation status of the BE and
HGD/EAC tissues from smokers compared to non-
smokers with respect to genomic regions and CpG is-
land location is shown in Fig. 5. In both BE and HGD/
EAC cases, the DML from smokers showed much higher
methylation in all genomic regions analyzed (Fig. 5).
There are numerous differentially methylated regions
(DMR) in esophageal tissues based on tobacco use status
As with the BMI-based comparison described above, we
were interested in extending our analysis of differential
DNA methylation between smokers and nonsmokers to
include differentially methylated regions in addition to
DML, which are single CpG sites. Among the BE cases,
there were DMR found involving 13 genes when com-
paring smokers to nonsmokers (FWER < 0.10, Δβ > 0.10,
and at least two contiguous CpG dinucleotides differen-
tially methylated). These DMR were located within the
genes TNXB and HOXA4, which are notable because
TNXB is a member of the tenascin family and regulates
cell-extracellular matrix interactions [42, 43] and HOXA4
is a transcription factor previously shown to inhibit
cell motility and to be aberrantly methylated in acute
myeloid leukemia [44, 45] (Fig. 6). TNXB is normally
more highly expressed in BE tissues compared to nor-
mal squamous esophagus (fold change = 3.39) whereas
HOXA4 has not been shown to be differentially
expressed in BE vs. normal esophagus (expression data
obtained from www.oncomine.org). Among the HGD/
EAC cases, we identified 29 DMR, including areas
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Table 3 Differentially methylated loci (p < 5 × 10−6): females vs. males (BE, HGD/EAC combined)









cg17272795 ZNF37A 0.34 0.10 (↓) 1.76E-09 TSS1500 1.06* −1.05* Shore
cg07753967 FRG1B 0.44 0.10 (↓) 2.13E-09 TSS1500 NS NS Island
cg25791279 PISD 0.26 0.15 (↓) 8.77E-09 TSS200 NS 2.17–3.20* Shore
cg25489030 FRG1B 0.46 0.30 (↓) 3.63E-08 Body NS NS Island
cg02531214 ZNF37A 0.34 0.13 (↓) 1.76E-07 TSS1500 1.06* −1.05* Shore
cg20811988 FRG1B 0.33 0.11 (↓) 7.17E-07 Body NS NS Island
cg03395511 DUSP22 0.11 0.42 (↑) 8.15E-07 TSS200 NS NS Shore
cg14815891 FRG1B 0.33 0.08 (↓) 1.03E-06 Body NS NS Island
cg01516881 DUSP22 0.07 0.23 (↑) 1.23E-06 Body NS NS Island
cg21508714 RBM20 0.31 0.12 (↓) 1.42E-06 Body NS NS Island
cg11386792 RBM20 0.44 0.13 (↓) 1.74E-06 Body NS NS Island
cg16004008 NRGN 0.35 0.20 (↓) 1.91E-06 TSS1500 1.45–1.46* 1.57–3.23* Shore
cg03066577 C3orf55 0.26 0.11 (↓) 2.17E-06 5′UTR; 1st exon; body NS 4.95* Island
cg21548813 DUSP22 0.08 0.36 (↑) 2.25E-06 TSS1500 NS NS Shore
cg14819088 SLC34A1 0.67 0.78 (↑) 2.52E-06 TSS200 NS NS Open sea
cg15383120 DUSP22 0.08 0.38 (↑) 2.52E-06 TSS200 NS NS Shore
cg18110333 DUSP22 0.09 0.39 (↑) 3.92E-06 1st exon; 5′UTR NS NS Island
cg16602806 MTRR 0.19 0.09 (↓) 4.59E-06 Body; TSS1500; 5′UTR 1.65* 1.77* Shore
cg25959506 RASD2 0.27 0.11 (↓) 4.91E-06 TSS1500 NS NS Island
5′UTR = 5′ untranslated region; TSS200/TSS1500 = 200 or 1500 bp’s upstream from transcription start site; Shore = DNA sequence up to 2 kb from CpG island; Open
sea = DNA sequence >4 kb from CpG island; NS = not significant; ^ = relative gene expression data obtained from www.oncomine.org; *p ≤ 0.05; (↑)/(↓) = increase/
decrease in methylation in male vs. females
Fig. 4 Dendrograms depicting DML when comparing smokers and nonsmokers. Because absolute differences in methylation (i.e., beta values)
between cases were small, these heatmaps illustrate relative differences in methylation between cases instead of absolute beta values. a smokers
vs. nonsmokers, all cases (BE, LGD, HGD, and EAC) combined. b Smokers vs. nonsmokers, BE cases. c Smokers vs. nonsmokers, HGD/EAC cases
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with altered methylation in the genes GFI1, which is a
transcriptional repressor implicated in the regulation
of p53 activity and Notch signaling [46, 47] and
CLDN11, a cell adhesion protein involved in cell mi-
gration that is commonly altered in cancer [48] (Fig. 6).
Normally, both GFI1 and CLDN11 have been shown
to be more highly expressed in EAC tissues vs. normal
esophagus (fold changes = 1.30 and 1.11–3.39, respect-
ively; www.oncomine.org).
Differences in esophageal DNA methylation between
smokers and nonsmokers are associated with several
cancer-related pathways and gene sets
We were interested to see which molecular and
cancer-related pathways were associated with the epi-
genetic differences in the BE and EAC tissues from
smokers as compared to nonsmokers. As with the
BMI cases, we restricted our NCI Pathway Interaction
Database (NCI-PID) analysis to only those DML that
we considered to be “cancer related” to improve the
likelihood these pathways would contain biologically
plausible mechanisms involved in smoking-related BE
and/or EAC formation.
Analysis of BE cases alone did not identify any
NCI-PID pathways that were differentially methylated
in BE smokers vs. nonsmokers. However, there was 1
KEGG pathway (“type 1 diabetes mellitus”) and 20
GO terms (including “positive regulation of mismatch
repair” and “enteric smooth muscle cell differentiation”)
that were differentially represented between the BE sam-
ples from smokers vs. nonsmokers (p < 0.05) (Additional
file 3: Table S4).
When we compared DNA methylation in the HGD/
EAC tissues of smokers and nonsmokers, we found two
NCI-PID pathways associated with alterations in DNA
methylation and smoking (FDR ≤ 0.05), including the
“neurotrophic factor-mediated Trk receptor signaling”
and “SHP2 signaling” pathways. The differentially meth-
ylated genes NTRK2 and NTRK3 were notable affected
members of both of these pathways. There were no
Table 4 Differentially methylated loci (p < 1 × 10−4): ever smokers vs. never smokers (BE, LGD, HGD/EAC combined)













cg05951860 CTTNBP2 0.49 0.15 (↓) 5.80E-07 Body Island NS NS Y
cg15310873 C20orf85 0.74 0.60 (↓) 5.06E-06 Body Island NS 3.34* N
cg23039279 PROK2 0.48 0.21 (↓) 1.92E-05 5′UTR; 1st exon Island NS 1.90* Y
cg16024318 SLC6A7 0.39 0.20 (↓) 2.68E-05 5′UTR; 1st exon Island 1.31* 1.17* Y
cg20285514 GNG4 0.52 0.19 (↓) 2.82E-05 TSS200; 5′UTR Island NS NS Y
cg07657743 WNT7A 0.56 0.22 (↓) 3.93E-05 Body Island NS NS N
cg19169023 TYRO3 0.74 0.57 (↓) 4.24E-05 Body Shore NS NS N
cg25757598 RALYL 0.51 0.25 (↓) 4.59E-05 5′UTR; 1st exon Island 1.16* 2.30* N
cg14196840 CTTNBP2 0.37 0.11 (↓) 5.08E-05 Body Island NS NS Y
cg04842146 RALYL 0.46 0.15 (↓) 5.55E-05 TSS1500 Shore 1.16* 2.30* Y
cg20620272 C3orf50 0.42 0.16 (↓) 5.77E-05 Body Island NS NS N
cg09374774 FAM78A 0.19 0.43 (↑) 5.80E-05 TSS200 Island NS 1.04* N
cg18016194 RALYL 0.50 0.29 (↓) 7.17E-05 5′UTR; 1st exon Island 1.16* 2.30* N
cg27603796 CTTNBP2 0.47 0.21 (↓) 7.21E-05 Body Shore NS NS Y
cg00818822 RFX2 0.90 0.80 (↓) 8.05E-05 Body Island 1.24* 6.23* N
cg10879116 LPAR3 0.51 0.26 (↓) 8.54E-05 5′UTR Island NS NS Y
cg11981631 ABCC8 0.59 0.30 (↓) 9.36E-05 Body Island 1.38* 1.11–1.70* Y
cg06600429 GABRB2 0.32 0.55 (↑) 9.75E-05 TSS1500 Shore NS NS Y
5′UTR = 5′ untranslated region; TSS200/TSS1500 = 200/1500 bp’s upstream from transcription start site; Shore = DNA sequence up to 2 kb from CpG island; NS = not
significant; ^ = relative gene expression data obtained from www.oncomine.org; *p ≤ 0.05; (↑)/(↓) = increase/decrease in methylation never smokers vs. smokers
Table 5 Differentially methylated loci: smokers vs. nonsmokers separated by tissue type












BE 86 25 (29 %) 43 (50 %) 18 (21 %) 23 (27 %) 28 (32 %) 21 (24 %)
HGD/EAC 802 152 (19 %) 417 (52 %) 233 (29 %) 279 (35 %) 395 (49 %) 79 (10 %)
DML defined by p value <0.001 and Δβ value (smoker vs. nonsmoker) > 0.10 while controlling for age
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KEGG pathways but there were 217 GO terms (such as
“localization of cell” and “regulation of cell migration”)
that were differentially represented (Additional file 4:
Table S5).
Discussion
Genetic and epigenetic alterations are commonly found
in BE and EAC and likely play a prominent role in
driving the initiation and progression of BE to EAC. It is
also well known that a variety of environmental factors
associate with the risk of developing BE and/or EAC.
Thus, we assessed the relationship between DNA methy-
lation in the esophagus and known risk factors for BE
and EAC using a genome-wide methylation platform.
We also sought to describe the epigenetic differences
between males and females in esophageal tissues in light
of the known differences in BE and EAC incidence in
men vs. women. With respect to demographic and
behavioral variables, we were particularly interested in
the correlation of BMI and tobacco use with DNA
methylation since both are well-established risk factors
for BE and EAC.
We assessed the methylation status of more than
485,000 CpG sites located in 99 % of the RefSeq genes
in 81 esophageal tissues representative of the stages of
esophageal adenocarcinoma development (BE, BE +
LGD, BE +HGD, EAC). The annotation of array probes
permitted us to determine whether differentially met-
hylated loci were located in specific types of genomic
regions (promoter, gene body, or intergenic) and to
determine the relationship of differentially methylated
loci (DML) to CpG islands (CpG island, shore, shelf, or
Fig. 5 Genomic location, relationship to CpG islands, and methylation status of DML when comparing smokers and nonsmokers in esophageal
samples. “Hypo” refers to percentage of DML that are hypomethylated in smokers vs. nonsmokers; “Hyper” refers to percentage of DML that are
hypermethylated in smokers vs. nonsmokers. On the Y axis, DMLs (%) refers to the percentage of the total DML that are associated with a
particular genomic location (a, d) or CGI relationship (b, e). Percentages may up to more than 100 % because some probes were classified with
more than one designation. Beta values are equivalent to percent methylation. Note: for all regions, the distribution of hypo/hypermethylated
DML compared to the expected distribution (based on all array probes) was not statistically significant. a DML when comparing smoker to
nonsmoker BE cases by genomic region. b Location of DML when comparing smoker to nonsmoker BE cases with respect to CpG island location.
c Box and whisker plots showing distribution of DML that are hypomethylated in the smoker vs. nonsmoker BE cases (left) and hypermethylated
in the smoker vs. nonsmoker BE cases (right). d DML when comparing smoker vs. nonsmoker HGD/EAC cases by genomic region. e Location of
DML when comparing smokers vs. nonsmoker HGD/EAC cases with respect to CpG island location. f Box and whisker plots showing distribution
of DML that are hypomethylated in the smoker vs. nonsmoker BMI HGD/EAC cases (left) and hypermethylated in the smoker vs. nonsmoker HGD/
EAC cases (right)
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open sea). Our analysis of the regions outside of promoter-
related CpG islands is notable because an understanding of
methylation alterations in areas with relatively low CpG
density is becoming increasingly recognized to be import-
ant in diseases such as cancer [49, 50]. It has been shown
that CpG-rich regions (i.e., CpG islands) demonstrate more
stable DNA methylation across tissues and cell populations
whereas methylation is more dynamic in CpG shores
(within 2 kb of a CpG islands) and CpG shelves (within
4 kb of a CpG island). Furthermore, the methylation
status of CpG shores and shelves appears to regulate
gene expression [29, 51].
We initially investigated the relationship between
DNA methylation and BMI in esophageal tissues. Ele-
vated body mass index (BMI) is an established risk factor
for BE and EAC, and we demonstrated that DNA
isolated from individuals with BMI > 30 was differentially
methylated at nearly 1000 CpG sites in combined BE,
BE with low- and high-grade dysplasia, and EAC tissues
when compared to samples from individuals with a low
BMI status. Interestingly, nearly 90 % of the DML
showed elevated methylation in the high BMI cases, and
over 36 % of the total DML were cancer related. There
were 20 % more cancer-related DML in the high BMI
group than we would expect by chance alone since just
16 % of the total probes on the array are “cancer related”
by our criteria as previously described. In the BE cases,
DML located in promoters and CpG islands tended to
be hypermethylated in those with high BMI which
suggests a possible association between methylation and
altered gene expression in those with elevated BMI as
promoter hypermethylation has been associated with
gene silencing [52]; this remains speculative given we
did not have associated gene expression data. There was
also evidence of altered methylation in BE and EAC
samples from obese patients when we looked at differen-
tially methylated regions (DMR), which are genomic
regions that have multiple adjacent CpG sites showing
Fig. 6 Selected genes containing differentially methylated regions (DMR) when comparing smoker and nonsmoker cases, depicting the location
of multiple contiguous differentially methylated CpG sites. Each panel contains the gene name and chromosomal location, alternate transcripts,
exons and introns (large and small orange boxes), location of CpG islands (green boxes), DML (blue and pink dots), and the DMR (yellow box).
Smokers are shown in pink and nonsmokers in blue. a TNXB gene, BE cases. b HOXA4 gene, BE cases. c GFI1, HGD/EAC cases. d CLDN11 gene,
HGD/EAC cases
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concordant methylation changes. DMR are potentially
more biologically important than differentially met-
hylated individual CpG dinucleotides because they are
indicative of larger scale epigenetic alterations that might
be more relevant functionally [36, 53].
We were also interested in whether the high BMI BE
cases displayed methylation alterations resembling the
EAC cases, our rationale being these epigenetic al-
terations in the obese with BE might be markers for
progression to dysplasia or cancer and provide some
evidence of a biological role for the genes subjected to
aberrant methylation. This was not the case, however, as
the high BMI cases clustered more closely with the low
BMI cases, not the EAC cases.
We subjected the DML to KEGG, Gene Ontology
(GO), and NCI-PID analyses to determine whether par-
ticular molecular groups or pathways were associated
with the methylation changes in obese individuals with
BE, dysplastic BE, or EAC. Among the BE cases, we
found epigenetic alterations in the direct p53 effectors
pathway in individuals with elevated BMI. This included
differentially methylated loci within the RDX gene,
which encode a cytoskeletal component that has been
shown to inhibit metastasis in gastric cancer [54].
TP53, the gene for p53, is a well-known tumor sup-
pressor gene that is frequently lost early in BE through
mutation or loss of heterozygosity (LOH) [55]. TP53
LOH has been shown to identify a subset of BE patients
who are at risk for progression to EAC [56, 57]. The
finding of differential methylation involving the p53
pathway in BE from subjects with high vs. low BMI sug-
gests a relationship between obesity and DNA methyla-
tion of cancer-related genes in the esophagus. Similar
results have been found in other studies comparing
methylation in obese to lean individuals. In a recent
study of 345 breast cancer cases, the majority (87 %) of
CpG sites analyzed showed elevated methylation in
obese patients, particularly in estrogen receptor-positive
tumors. Obesity was associated with the aberrant methy-
lation of cancer-related genes involved with the immune
response, cell growth, and DNA repair [22]. Several prior
studies have compared DNA methylation in whole blood
or peripheral blood leukocytes among obese and non-
obese individuals [58–60]. In two of these studies, the
gene HIF3A was found to be hypermethylated in the
blood cells and adipose tissue of obese adults, suggesting
perturbation of the hypoxia inducible transcription fac-
tor pathway in those with elevated BMI.
We were also interested in determining if there were
genome-wide differences in esophageal DNA methylation
between males and females. Previously, when we used a
genome-wide approach to compare methylation in the
normal colon between males and females, we found 82
DML between the groups, with females showing increased
methylation at 69.5 % of the differentially methylated
CpGs [61]. In the present study, we found 402 DML after
controlling for age and histology, with 81.3 % showing
higher methylation in females. Other studies have shown
differences in autosomal DNA methylation by gender in
the brain, saliva, and blood [9, 62, 63]. These results
suggest that DNA methylation might function in the
differentiation or maintenance of sexual dimorphism. An
understanding of tissue-specific gender differences is also
important in terms of understanding the role of environ-
mental, behavioral, and demographic factors on alterations
in DNA methylation in order to appropriately account for
potentially confounding effects of gender [63].
Tobacco smoking is another known risk factor for
developing Barrett’s esophagus and esophageal adenocar-
cinoma [64]. The mechanisms accounting for this risk
are only partly understood and are believed to involve
carcinogen-mediated mutations. Cigarette smoke con-
tains multiple carcinogens which likely exert their effects
via the induction of DNA adducts, aberrant DNA
methylation and mutation, and chromosomal transloca-
tion [65, 66]. In order to define the association between
tobacco use and aberrant DNA methylation in BE/EAC,
we analyzed 54 esophageal samples of various histo-
logical types for global alterations in DNA methylation
associated with tobacco smoking. We found 256 DML
in these tissues between smokers and nonsmokers.
Ninety-five percent (95 %) of these DML showed ele-
vated methylation in the smoker group and 41.0 % were
cancer related, which is 25 % more cancer-related DML
than would be expected by chance alone.
The finding of widespread and frequent hypermethyla-
tion in BE, dysplastic BE, and EAC tissues of tobacco
smokers suggests that tobacco-related epigenetic alter-
ations may be a mechanism through which tobacco
affects the development of BE and EAC. After enriching
the DML (smokers vs. nonsmokers) for cancer-related
genes, we found the Trk and Shp2 pathways to be differ-
entially activated between these groups; these differences
were driven by hypermethylation of the NTRK2 and
NTRK3 genes in smokers. The differentially methylated
NTRK2 locus, located in a promoter CpG island, dem-
onstrated an average methylation level of 36 % in the
HGD/EAC samples from smokers vs. 9 % in non-
smokers. The differentially methylated NTRK3 locus,
located in the gene body, showed an average methylation
of 85 % in the HGD/EAC samples of smokers compared
to 62 % in nonsmokers. We previously found the aber-
rant methylation of NTRK3 in 60 % of colon adenomas
and 67 % of colon adenocarcinomas, suggesting NTRK3
is a novel conditional tumor suppressor gene that is
commonly inactivated in colorectal cancer by both epi-
genetic and genetic mechanisms [67]. NTRK2 has also
been shown to be hypermethylated in colon cancers as
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well as prostate cancer cell lines and cancers [68, 69]. With
respect to esophageal cancer, NTRK2 was found to have an
altered allele frequency in a group of mainly esophageal
squamous cell cancers, suggesting a role in esophageal
cancer susceptibility and/or development [70]. The effect of
DNA methylation on NTRK2 in BE and HGD/EAC is not
clear at this time as its expression in BE or HGD is similar
to normal esophagus based on publically available gene
expression data, whereas NTRK3 is normally overexpressed
in EAC (but not BE) vs. normal esophagus (expression level
1.03–1.79; www.oncomine.org).
We did not have mRNA expression data available for
these samples to allow us to determine whether methyla-
tion alterations were associated with concordant changes
in expression, which is a limitation of this study. In order
to increase the likelihood that differences in methylation
between the groups we studied were biologically relevant,
we focused upon cancer-related pathways and pathways
known to be involved in obesity and inflammation. An-
other potential limitation of this study in the EAC cases
presumably contained a mix of cell types, including cancer
cells, stromal cells, and inflammatory cells. We aimed to
reduce the effects of cell heterogeneity by including only
samples with >75 % cancer cells and focusing on genes
with relatively large differences in methylation.
Conclusions
In summary, we used a microarray-based approach to de-
termine genome-wide methylation profiles of a collection
of 81 esophageal specimens, including samples of BE, dys-
plastic BE, and EAC DNA. With respect to gender, BMI,
and tobacco use we found numerous alterations in DNA
methylation involving various regions of the genome.
These results suggest that obesity and tobacco smoking
influence DNA methylation in the esophagus and provide
novel insights into the pathways linking these risk factors
to the development of BE, dysplastic BE, and EAC.
Methods
Primary tissue samples and sample preparation
DNA was extracted from formalin-fixed, paraffin-
embedded (FFPE) tissue cores obtained from the De-
partment of Pathology at University Hospitals Case
Medical Center using the DNAeasy blood and tissue
kit (Qiagen #69504) according to the manufacturer’s
instructions with minor modifications [71]. Protocols
were approved by the institutional review board. All
samples were reviewed by an expert gastrointestinal
pathologist (JEW) prior to processing. The total number of
samples prepared was: 21 Barrett’s esophagus (BE), 18 Bar-
rett’s with low-grade dysplasia (BE + LGD), 18 Barrett’s with
high-grade dysplasia (BE +HGD), and 24 with esophageal
adenocarcinoma (EAC) (Additional file 5: Table S1). We
also analyzed 12 cases of esophageal squamous epithelia
(SQ) and compared methylation of this sample group to
the EAC group to generate a list of “cancer-associated” loci.
Epithelial cell layers were identified and subsequently
microdissected from glass slides. For the EAC cases, at
least 75 % of each sample contained cancer in order to
minimize methylation differences that might be due to
cellular heterogeneity. After extraction, the DNA con-
centration was determined using the Quant-iT Pico-
Green dsDNA assay kit (Invitrogen/Life Technologies,
#P7589), and DNA quality was confirmed using the
Illumina FFPE QC kit (Illumina, #WG-321-1001). Next,
a total of 250 ng of each sample was sodium bisulfite
converted using the EZ DNA methylation kit following
the manufacturer’s protocol (ZymoResearch, #D5002),
and then the DNA samples were treated with the Infi-
nium HD FFPE DNA restore kit to repair any degraded
DNA (Illumina, #WG-321-1002). Bisulfite-converted, re-
stored DNA was submitted to the Genomics Core at the
Fred Hutchinson Cancer Research Center (FHCRC) for
processing, application, and scanning on the Human-
Methylation450 (HM450) BeadChip following the manu-
facturer’s instructions (Illumina #WG-314-1003; http://
www.Illumina.com).
Genome-wide methylation arrays
HM450 BeadChips were used to analyze patterns of DNA
methylation in 81 of the esophageal samples listed above.
We followed our previously validated protocols for data fil-
tering, normalization, and differential methylation analysis
[61, 72] with the following modifications or clarifications:
probes with detection p value >0.05, probes on the X
chromosome, and probes containing at least one SNP with
low minor allele frequency (MAF = 0) in the probe body
were filtered out. After filtering, a total of 453,444 probes
were available for downstream analysis. The ComBat algo-
rithm was used to correct known batch effects across the
three different microarray experiments while retaining the
expected variation between the different histological tissue
types [73, 74]. Data was analyzed using both “β values,”
where 0.0 is equivalent to 0 % methylation and 1.0 is
equivalent to 100 % and “M values” which are logarithmic
scores similar to those used in gene expression microarrays.
We performed clustering analysis using the 3000 most
highly variable loci when considering all BE, LGD, HGD,
and EAC cases assessed using the HM450 array. We used
the limma and minfi Bioconductor packages to compute a
refined F-statistic to quantify the difference in DNA methy-
lation based on a probe’s M-value between sample types.
We used a false discovery rate (FDR) q value to determine
the significance of differentially methylated loci (DML) and
considered loci to be differentially methylated if q < 1 × 10−5
[75]. Cancer-associated loci were those that showed differ-
ential methylation when comparing EAC and squamous
(SQ) samples (q < 0.001).
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The relationships of differentially methylated CpG
dinucleotides to CpG islands were determined using the
HM450 array annotation along with published defini-
tions [29, 30]. Thus, a CpG island shore is the region
located 0–2 kb from a CpG island, a CpG island shelf is
located 2–4 kb from a CpG island, and an “open sea” is
located >4 kb from a CpG island.
Differentially methylated regions (DMR) were calcu-
lated using the Bumphunter method as described by
Jaffe et al. [76]. To be considered a DMR, regions had to
contain at least two contiguous CpG dinucleotides that
were differentially methylated with family-wise error rate
(FWER) < 0.10 and Δβ > 0.10.
The actual vs. expected distributions of BMI and
smoking-associated DML with respect to genomic lo-
cation and CpG island were calculated using Pearson
chi-square tests. In other words, we compared the
distribution of differentially hypo- or hypermethylated
loci and the distribution of all of the probes on the
HM450 array with respect to genomic location/CpG
island location to determine whether particular regions
were enriched in hypo/hypermethylated loci.
Gene pathway analysis
Pathway enrichment analysis of significantly differentially
methylated genes between any two sample groups was
performed using pathway definitions derived from the
NCI Pathway Interaction Database (NCI-PID), a curated
collection of known biomolecular interactions and key
signaling pathways associated with cancer [77]. The en-
richment analysis was performed using the hypergeo-
metric test to evaluate if genes belonging to a given
pathway were enriched among the significantly differen-
tially methylated loci. We elected to increase the possibil-
ity that altered molecular pathways would be biologically
relevant by restricting our NCI-PID analysis to only
cancer-associated DML. Hochberg FDR methodology and
pathways with FDR ≤ 0.05 were considered significantly
methylated genes. This was followed by followed by
assessment of false discovery rate using the Benjamini
Hochberg correction [78]. Genes with multiple differen-
tially methylated probes were excluded if the methylation
state of any probe was inconsistent between comparison
groups. Gene set enrichment analysis was performed
using genes from differentially methylated groups to
identify affected Gene Ontology (GO) terms and Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways
across different comparison groups using hypergeometric
testing provided by the GOstats software [79]. Probes
whose target genes were not annotated to at least one GO
term in the biological process ontology were filtered out.
A gene set was considered altered if its number of differ-
entially methylated CpG sites was higher or lower than
expected using a p value <0.05.
Additional files
Additional file 1: Table S2. GO terms represented in DM genes
comparing BE high vs. low BMI. (DOC 28 kb)
Additional file 2: Table S3. GO terms represented in DM genes
comparing HGD/EAC high vs. low BMI. (DOC 28 kb)
Additional file 3: Table S4. GO terms represented in DM genes
comparing BE smokers vs. nonsmokers. (DOC 28 kb)
Additional file 4: Table S5. GO terms represented in DM genes
comparing HGD/EAC smokers vs. nonsmokers. (DOC 28 kb)
Additional file 5: Table S1. Samples analyzed on HM450 arrays.
(DOC 122 kb)
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